Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Summary

This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose.

Timeline

Start

2024-03-06

Primary completion

2024-08-28

Completion

2024-08-28

Outcome

Outcome not reported

Stopped: “Cohorts 1 and 2 were completed. Cohort 3 was cancelled because it was no longer necessary based on information from another study. No safety concerns were noted.”

Drugs

Indications

No indication recorded.